About this episode
In this episode of The Healthy Enterprise, host Brian Newsom discusses his journey in the biotechnology field, focusing on his role as CEO of Carrigent, a company specializing in cell and gene therapy. He elaborates on the innovative vector technology being developed for targeted payload delivery, the challenges of fundraising in the current market, and the integration of AI to enhance operational efficiency. Brian also shares insights into the importance of strategic partnerships and the ultimate goal of bringing therapeutic solutions to patients. In this conversation, the speaker discusses the importance of building long-term relationships in healthcare, particularly in the context of gene therapy. They share insights on leadership styles, emphasizing trust and autonomy within teams. The challenges of being a founder are explored, along with the need for inspiration and motivation in tough times. The discussion also touches on the intersection of science fiction and current scientific advancements, future trends in healthcare, and advice for aspiring professionals in the field.Chapters00:00 Introduction to Cell and Gene Therapy Innovations03:04 Exploring Vector Technology and Its Applications05:59 Brian Newsom's Journey: From Science to Business09:08 Leveraging AI and Technology in Biotech11:59 Navigating Fundraising Challenges in Biotech14:49 Strategic Partnerships and Market Positioning22:12 Building Long-Term Relationships in Healthcare23:27 Leadership Style and Team Dynamics26:00 The Challenges of Foundership28:32 Finding Inspiration and Motivation31:12 The Intersection of Science Fiction and Reality33:03 Future Trends in Healthcare35:34 Advice for Aspiring Professionals37:17 Navigating Tough Times in the IndustryGuest Information:Guest's Name: Brian NewsomGuest's Title/Position: Chief Executive OfficerGuest's Linkedin: https://www.linkedin.com/in/brian-newsom/Company / Affiliation: Carrigent https://carrigent.com/Guest's Bio: Brian Newsom is the founding CEO of the vector technology company, Carrigent, as well as the VP of Business Development for the cell therapy CDMO, Theragent. Prior to this, Brian spent six years at KBI Biopharma and almost a decade at Thermo Fisher Scientific (and legacy companies) in business development. Brian’s technical background includes posts as Head of R&D at Opexa Therapeutics and five years at Baylor College of Medicine, Center for Cell and Gene Therapy. Brian began his career in cell therapy at Aastrom Biosciences, one of the industries pioneering companies, in 1992. Brian received his degree in Microbiology from Texas Te
